Clinical Trials

At Adamas, we are committed to developing new medicines to improve the daily lives of those affected by chronic neurologic disorders, such as Parkinson’s disease, multiple sclerosis (MS), epilepsy and Alzheimer’s disease, through our unique drug development platform.

We are currently evaluating ADS-5102 (amantadine) for the treatment of:

  • Levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease
  • Patients with MS who have impaired walking.
About Adamas

Dedicated to developing new medicines to improve the daily lives of people affected by chronic neurologic disorders. Learn more